Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. develops precision genetic medicines through a base-editing platform that combines gene editing, delivery and internal manufacturing capabilities. News about Beam Therapeutics centers on clinical and business updates for risto-cel in sickle cell disease, BEAM-302 in alpha-1 antitrypsin deficiency, liver-targeted genetic disease programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa, and financing activity tied to late-stage development.
Company updates also cover financial results, portfolio prioritization, published clinical data, FDA designations and regulatory interactions, licensing arrangements for base-editing patent rights, and governance changes.
Beam Therapeutics (Nasdaq: BEAM) announced a proposed public offering of 4,500,000 shares of its common stock. The company will offer all the shares, with an option for underwriters to purchase an additional 675,000 shares. J.P. Morgan, Jefferies, and Barclays are the joint book-running managers. The registration statement has been filed with the SEC but is not yet effective. Investors are advised to review the preliminary prospectus for more details. This offering aims to raise capital to support Beam’s precision genetic medicine initiatives through base editing.
Beam Therapeutics has named BEAM-101 and BEAM-102 as its first development candidates for treating sickle cell disease, leveraging innovative base editing technologies. The company is establishing a 100,000 sq. ft. manufacturing facility in North Carolina to enhance production capabilities. Beam ended Q2 2020 with $228 million in cash but reported a net loss of $34.2 million. The firm continues to pursue partnerships to further its genetic medicine initiatives. The company aims to file an Investigational New Drug application in 2021.
Beam Therapeutics (Nasdaq: BEAM) announced its participation in two upcoming investor conferences in August 2020. The company will be featured in the William Blair Biotech Focus Conference on August 6 at 1:00 p.m. ET, discussing 'Gene Editing and Gene Therapy in 2030.' Additionally, it will present at the Wedbush PacGrow Healthcare Virtual Conference on August 12 at 9:45 a.m. ET. Live webcasts of these events will be accessible on the investor section of Beam's website and archived for 60 days thereafter.
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicine, announced that CEO John Evans will present at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 9:30 a.m. ET. The conference runs from June 2-4, 2020. The presentation will be available via live webcast on the company's investor website, with an archive accessible for 60 days post-event. Beam Therapeutics focuses on base editing technology, creating precise genetic modifications without double-stranded DNA breaks, aiming to provide lasting solutions for serious diseases.
Beam Therapeutics Inc. (Nasdaq: BEAM) reported significant advancements in its genetic medicine programs, showcasing a more than four-fold increase in circulating levels of functional protein for Alpha-1 Antitrypsin Deficiency. The company also demonstrated over 80% direct correction in sickle cell disease and greater than 90% editing in its fetal hemoglobin program. Financially, Beam holds $253.4 million in cash as of March 31, 2020, with R&D expenses rising to $21.5 million. The net loss for Q1 2020 was $31.7 million, or $1.03 per share, an increase from the previous year.
Summary not available.
Summary not available.